CANY
NUVB icon

Caxton Associates (New York)’s Nuvation Bio NUVB Stock Holding History

Caxton Associates (New York)’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$117K Sell
44,160
-26,241
-37% -$67.6K ﹤0.01% 464
2024
Q3 		$161K Buy
70,401
+55,843
+384% +$170K 0.01% 498
2024
Q2 		$42.5K Buy
+14,558
New +$44.4K ﹤0.01% 465

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Caxton Associates (New York)'s NUVB Position: Q4 2024 in Review

Caxton Associates (New York) reduced its Nuvation Bio (NUVB) stake by 37% in Q4 2024, selling an estimated $67.6K and leaving 44,160 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Caxton Associates (New York) first reported a position in NUVB in Q2 2024 and has held it in 3 quarters since. The position peaked at $161K in Q3 2024. 160 funds tracked by Wall St. Rank hold NUVB as of Q4 2024.

  • Caxton Associates (New York) held 44,160 shares of Nuvation Bio worth $117K as of Q4 2024.
  • Caxton Associates (New York) sold 26,241 Nuvation Bio shares in Q4 2024, an estimated $67.6K.
  • Nuvation Bio made up ﹤0.01% of Caxton Associates (New York)'s portfolio in Q4 2024, its #464 holding.
  • Caxton Associates (New York) first reported a position in Nuvation Bio in Q2 2024 and has held it in 3 quarters since.
  • Caxton Associates (New York)'s Nuvation Bio position peaked at $161K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Nuvation Bio as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.